Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | P2RY12 | Q9H244 | 4/20 | 0.36 |
| ▸ | FOS | P01100 | 1/20 | 0.36 |
| ▸ | JUN | P05412 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2089856 | 0.85 | KDM4E (0.46) | KDM4EALDH1A1GRM2MAPTGAA | |
| SCHEMBL3978946 | 0.85 | ALDH1A1 (0.41) | KDM4EALDH1A1GRM2MAPTGAA | |
| SCHEMBL2089325 | 0.82 | KDM4E (0.50) | KDM4EALDH1A1GRM2MAPTGAA | |
| SCHEMBL3979049 | 0.81 | KDM4E (0.49) | KDM4EALDH1A1GRM2MAPTGAA | |
| SCHEMBL3977048 | 0.80 | KDM4E (0.48) | KDM4EALDH1A1GRM2GAAIDO1 | |
| SCHEMBL2087062 | 0.80 | KDM4E (0.48) | KDM4EALDH1A1GRM2MAPTGAA | |
| SCHEMBL4221142 | 0.79 | GRM2 (0.46) | KDM4EALDH1A1GRM2MAPTGAA | |
| SCHEMBL1197727 | 0.79 | KDM4E (0.47) | KDM4EALDH1A1GRM2MAPTGAA | |
| SCHEMBL21408591 | 0.78 | GRM2 (0.48) | KDM4EALDH1A1GRM2GAAIDO1 | |
| SCHEMBL14535209 | 0.77 | ALDH1A1 (0.42) | KDM4EALDH1A1GRM2MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541374-B2 | Malononitrile compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-06-02 | — | — | US | disclosed |
| US-20070117854-A1 | Malononitrile compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117854-A1 | Malononitrile compounds and use thereof | ME1, DDT, CYP51A1 | KDM4E 1179/4885ALDH1A1 143/4885GRM2 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.